Mirabegron: A Review in Overactive Bladder Syndrome

Area of Science:

• Pharmacology
• Urology

Background:

• Overactive bladder (OAB) syndrome significantly impacts patients' quality of life.
• Antimuscarinic agents are common treatments but can have limiting side effects.
• Mirabegron represents a novel therapeutic approach as a β3-adrenoceptor agonist.

Purpose of the Study:

• To evaluate the efficacy and tolerability of mirabegron in managing OAB.
• To compare mirabegron's effectiveness against placebo and antimuscarinic agents.
• To assess the long-term effects and real-world applicability of mirabegron treatment.

Main Methods:

• Analysis of data from large phase 3 clinical trials.
• Comparison of mirabegron versus placebo over 12 weeks.
• Evaluation of mirabegron against solifenacin in a 12-week powered comparison.
• Assessment of sustained efficacy and tolerability up to 52 weeks.
• Review of real-world evidence and patient persistence data.

Main Results:

• Mirabegron significantly reduced micturition frequency, incontinence, and urgency compared to placebo.
• Improvements in void volume and health-related quality of life (HR-QOL) were observed.
• Mirabegron did not demonstrate noninferiority to solifenacin in reducing micturition frequency.
• Sustained efficacy and HR-QOL benefits were noted up to 52 weeks.
• Mirabegron was generally well tolerated, with a lower incidence of dry mouth than antimuscarinics.
• Real-world data suggest potential benefits in patient persistence and adherence.

Conclusions:

• Mirabegron is an effective treatment for OAB, offering significant symptom relief and improved HR-QOL.
• It provides a valuable alternative to antimuscarinic therapies, particularly for patients dissatisfied with current treatments or experiencing side effects.
• Further research into its use in specific populations, such as older men, is warranted.